|
|
Ritonavir (Norvir) Research
- The Next Generation of Boosters: Promising Data on Potential Alternatives to Ritonavir (February 9, 2009)
Brian Kearney, Pharm.D., of Gilead Sciences Inc., and Robert Guttendorf, Ph.D., of Sequoia Pharmaceuticals discuss encouraging findings from early human trials on a pair of pharmacokinetic enhancers whose utility could potentially extend far beyond protease inhibitor boosting.
In The 16th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Among Patients on Boosted-PI Regimens, Dose Staggering and Selective Non-Adherence to Ritonavir Is Relatively Common (February 6, 2008)
From The Body PRO
- Short-Term Ritonavir Exposure Impacts HDL, CD36 and Triglyceride Levels in Healthy Volunteers (February 4, 2008)
Marta Boffito, M.D., Ph.D., discusses her study, which examines the possible role of ritonavir in increasing cardiovascular risk.
From The Body PRO
|
Advertisement
|
E-Mail
Glossary
Share